Methylstenbolone

Diagram of molecule

Chemical Name(s):
2,17a-Dimethyl-17b-hydroxy-5a-androst-1-en-3-one
Chemical Formula: C21H32O2
Molecular Weight: 316.5
CAS: NA
Q Qatio: 3.9
Anabolic #: 660
Androgenic #: 170
Oral Bioavailability: Estimated at 50%
AR Binding Affinity: NA
SHBG Binding Affinity: NA
Half Life: NA
Legal Status (US): Not listed as a controlled substance
Average Dose:
5-20mg/day standalone
1-5mg/day when stacked
Average Cycle Length: 2-4 weeks

 

Stimulator
Inhibitor

 

 
-5
-4
-3
-2
-1

0
1
2
3
4
5

Muscle Gain

[][][][][]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Strength Gain

[][][][][]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Fat Gain (negative indicates fat loss)

[]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Water Retention (extra-cellular bloat)

[][]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Aggression

[][][][]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Libido

[]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Acne

[]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Hair Loss

[][][]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Prostate Enlargement

[][][]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Liver Toxicity

[][][][][]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Lethargy

[]
-5
-4
-3
-2
-1

0
1
2
3
4
5

 

Characteristics

Although this compound cannot convert to estrogen, it will bind strongly to SHBG, thus increasing freely circulating estrogen (and testosterone). While there is a lack of anecdotal feedback from this compound to tell the real world effect this compound may have on causing gyno, experience with related compounds tell us gyno symptoms may occur.

Users should be very careful with methylstenbolone and start out with a very low dose. This compound will likely produce a rapid increase in intracellular water retention by inhibiting 11-beta hydroxylase and building up levels of mineralcorticoids that will encourage sodium and water retention.

Gains upwards of 20-25lbs in 4 weeks are probably possible with this compound. However the liver toxicity issues would likely be the first reason why someone wouldn’t be able to make incredible gains from this compound. For this reason it would be extremely important to pre-condition the liver with a liver protecting supplement prior to cycling this compound, while continuing use throughout the cycle and during PCT.

The strength increases from this compound will likely encourage weight lifting heavier than tendons and joints are prepared to lift. It is recommended to be cautious of this and to naturally build up strength levels prior to cycling this steroid.

Using a low dose of methylstenbolone with a moderate dose of a non-methylated compound would be an acceptable way to try to limit the side-effects from this compound, although caution would still need to be taken for liver health no matter what dose is used.

Because of the strength and weight gain this compound would offer it would likely be best used as part of a bulking cycle.

Availability: 

UltraDrol by Antaeus Labs

Related Discussion

The Official Methylstenbolone Thread
Posted by Eric

References

Anabolic Pharmacology
Seth Roberts (2009)

Advertisements

Methylepitiostanol (Epistane)

Diagram of molecule

Chemical Name(s):

2a,3a-epithio-17a-methyl-etioallocholan-17b-ol
2a,3a-epithio-17a-methyl-5a-androstan-17b-ol
Chemical Formula: C20H30OS
Molecular Weight: 320.5
CAS: NA
Q Qatio: 12
Anabolic #: 1,100
Androgenic #: 91
Oral Bioavailability: Estimated at 40%
AR Binding Affinity: NA
SHBG Binding Affinity: NA
Half Life: ~6 hours
Legal Status (US): Not listed as a controlled substance
Average Dose:
40-50mg/day standalone
10-20mg/day when stacked
Average Cycle Length: 4-6 weeks
Stimulator
Inhibitor

-5
-4
-3
-2
-1

0
1
2
3
4
5

Muscle Gain

[][][]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Strength Gain

[][][]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Fat Gain (negative indicates fat loss)

[][]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Water Retention (extra-cellular bloat)

[][]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Aggression

[]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Libido

[][]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Acne

[]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Hair Loss

[][]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Prostate Enlargement

[][]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Liver Toxicity

[][][]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Lethargy

[]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Characteristics

Methylepitiostanol is a methylated version of the steroid Epitiostanol. It is readily active and does not require conversion. Under the influence of heat methylepitiostanol readily breaks down to 17a-Methyl-androstan-2-en-17b-ol (DMT), a now illegal anabolic steroid.

It does not aromatize, however it is possible that methylepitiostanol may offset estrogen and testosterone from SHBG thus increase the risk of gyno for certain individuals with high SHBG levels. Gyno symptoms from this compound may also be a result of this compounds inability to form a potent androgen such as DHT (to antagonize the effects of estrogen). However, in other cases methylepitiostanol can be used to prevent or reduce gynecomastia from an estrogenic steroid by acting as an aromatase inhibitor to keep estrogen down.

It is a DHT derivative with a fairly moderate androgenic value so the chances of hair loss may be increased in certain sensitive users. Swelling of the prostate may also become an issue. The powerful estrogen suppressing action of this steroid and its 17aa stucture will cause it to negatively influence the cholesterol profile by lowering HDL and increasing LDL. It has also been reported to cause stiff joints, possibly related to its suppressive effect on estrogen levels.

Anecdotal reports of appetite suppression and general fatigue would lead one to believe that the liver stress from this 17aa compound is rather severe. For this reason it is recommended to use a liver protecting supplement prior to and during the use of this steroid.

Methylepitiostanol has a strong anabolic action that will lead to quick gains in lean muscle mass and strength with very little bloat. The gains will appear with minimal fat gain and increased vascularity.

Because methylepitiostanol can negatively affect joint comfort it is recommended to be stacked with an aromatizing or progestational compound. However, it is not recommended to stack this steroid with another 17aa oral.

Common Clones:

Epistane by Innovative Body Enhancement (IBE)
Havoc by Primaforce
Havoc by Recomp Performance Nutrition (RPN)
Epi-MAX by Anabolic Formulations
M14-E by Purus Labs
Methyl-E by Engineered Sports Technology (EST)
E-Max by Juggernaut Nutrition
E-Stane by Competitive Edge Labs (CEL)
Hemaguno by Spectra Force Research
Hemapolin by Starmark Labs
Epi-Mass by Armour Nutrition
Epidrol by Genera Labs
Methyl Freak by Rockhard Formulations
Epistrong by Mrsupps


Related Discussion

The Official Methylepitiostanol (Epistane) Thread
Posted by Eric

References

“2{alpha},3{alpha}-Epithio-5{alpha}-androstan-17ß-yl 1-Methoxycyclopentyl Ether in the Treatment of Advanced Breast Cancer —A Preliminary Clinical Trial”

SOICHI KUMAOKA, M.D., OSAMU TAKATANI, M.D., MINORU YOSHIDA, M.D., SHIGETO MIURA, M.D., TETSUTO TAKAO, M.D., YÜJI HAMANAKA, M.D., MASARU IZUO, M.D. and TADAKAZU OKADA, M.D.
Japanese Journal of Clinical Oncology 4:65-68 (1974)

“Inhibited growth in vivo of a mouse pregnancy-dependent mammary tumor (TPDMT-4) by an antiestrogen, 2alpha, 3alpha-epithio-5alpha-androstan-17beta-ol (10275-S).”
Matsuzawa A, Yamamoto T.Cancer Res. 1976 May;36(5):1598-606.

“Antitumor Effect of Two Oral Steroids, Mepitiostane and Fluoxymesterone, on a Pregnancy-dependent Mouse Mammary Tumor (TPDMT-4)1”
Akio Matsuzawa and Tadashi Yamamoto
Cancer Research 37, 4408-4415, December 1, 1977

Methyldrostanolone (Superdrol)

Diagram of molecule

Chemical Name(s):

2a,17a-dimethyl-5a-androst-3-one-17b-ol
2a,17a-dimethyl-etiocholan-3-one-17b-ol
Chemical Formula: C21H34O2
Molecular Weight: 318
CAS: NA
Q Qatio: 20
Anabolic #: 400
Androgenic #: 20
Oral Bioavailability: Estimated at 50%
AR Binding Affinity: NA
SHBG Binding Affinity: High
Half Life: ~8 hours
Legal Status (US): Not listed as a controlled substance
Average Dose:
10-30mg/day standalone
5-10mg/day when stacked
Average Cycle Length: 2-4 weeks
Stimulator
Inhibitor

-5
-4
-3
-2
-1

0
1
2
3
4
5

Muscle Gain

[][][][]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Strength Gain

[][][][][]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Fat Gain (negative indicates fat loss)

[]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Water Retention (extra-cellular bloat)

[][]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Aggression

[][][]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Libido

[]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Acne

[]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Hair Loss

[]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Prostate Enlargement

[][]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Liver Toxicity

[][][][][]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Lethargy

[][]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Characteristics

Methyldrostanolone is a C-17 alpha alkylated steroid, originally developed by the American pharmaceutical company Syntex. This steroid is already active and does not require conversion. Methyldrostanolone is the 17aa version of the injectable steroid drostanolone (Masteron). This extra methylation makes this steroid about 3-4x more anabolic than Masteron, and slightly more anabolic than oxandrolone (Anavar). Due to the dimethylation, the toxicity of methyldrostanolone is greater than most other oral steroids. There have been many reported cases of heptatoxicity with this compound. (1-3)

Despite the fact that methyldrostanolone is a DHT derivative and cannot convert to estrogen, some users have still reported gyno like symptoms during or after a cycle. This effect is likely related to the strong SHBG binding effect and increase in freely circulating estrogen (and testosterone) from SHBG. Gyno symptoms may also be related to the fact that methldrostanolone lacks a strong DHT metabolite to antagonize the effects of estrogen (while also having a relatively low intrinsic androgenic value).

Having a fairly low androgenic value will mean that methyldrostanolone will be light on the hairline for most men. However those susceptible to male pattern baldness may still noticed accelerated hair loss during a cycle.

Because of the di-methylation, methlydrostanolone is considerably more resistant to breakdown, thus more potent per mg than most other steroids. However this makes it more liver toxic than other single methylated 17aa orals. Negative effects on the liver generally manifest as a condition known as reversible cholestasis. This is essentially a slowing or complete blockage of bile acids from the liver. Immediate signs of compromised liver function included reduced appetite and general sickness, which will soon be accompanied by yellowing of the eyes (jaundice), excessive itchiness and very dark urine. If these effects are noticed, methyldrostanolone should be discontinued immediately.

Because the effects on the liver it is very important to use a liver protecting supplement during any methyldrostanolone cycle. If not using a supplement to protect your liver, methyldrostanolone should never be used any longer than 2 weeks, with a maximum cycle length of 4 weeks with liver protection.

Other reversible side effects from methyldrostanolone may include increased blood pressure, reduced HDL cholesterol and lower back pumps.

Results wise, users should expect extreme strength increases and weight gain in a relatively short 2-4 week period. Weight gain upwards of 20lbs in 4 weeks is not unheard of with this incredibly potent compound. Although subcutaneous water gain would be minimal, intramuscular water retention should be expected. This is due to inhibition of 11b-hydroxylase and build-up of mineralcorticoids which encourage salt and water retention within the muscles. The most obvious physical effects will be improved vascularity, aggressive muscular pumps, and oily skin.

While methyldrostanolone can stack well with most other steroids, it should never be stacked with another methylated (17aa) steroid.

Common Clones:


Oxodrol 12 by IDS
Superdrol by Anabolic Xtreme
M-Drol by Competitive Edge Labs (CEL)
SD-1 by Performance Design
Methyl VOL by Engineered Sports Technology (EST)
Revenge SDX by Bioscience Technologies
S-Drol by Nutracoastal
E-Pol by Purus Labs
MethaDROL by IForce
Straight-DROL by Black China Labs
MethylDX3 by Physical Enhancing Industries
Oxevol (same as Dianevol) by Evolution Labs
Beastdrol by Mrsupps



Related Discussion

The Official Methyldrostanolone (Superdrol) Thread
Posted by Eric

References

Cholestatic Jaundice and IgA Nephropathy Induced by OTC Muscle Building Agent Superdrol.

Beata Jasiurkowski MD, et al.
The American Journal of Gastroenterology (2006) 101, 2659-2662;

Severe Cholestasis and Renal Failure Associated with the Use of the Designer Steroid Superdrol (Methasteron): A Case Report and Literature Review
John Nasr and Jawad Ahmad
Digestive Diseases and Sciences

Methasteron-Associated Cholestatic Liver Injury: Clinicopathologic Findings in 5 Cases”
Neeral L. et al.
Clinical Gastroenterology and Hepatology, Volume 6, Issue 2, February 2008, Pages 255-258

Identification of drostanolone and 17-methyldrostanolone metabolites produced by cryopreserved human hepatocytes”
Julie Gauthier, Danielle Goudreault, Donald Poirier and Christiane Ayotte
Steroids; Volume 74, Issue 3, March 2009, Pages 306-314

Dimethazine

Diagram of molecule

Chemical Name(s):
17beta-hydroxy 2alpha,17alpha-dimethyl 5alpha-androstan 3-one azine
Chemical Formula: C42H68N2O2
Molecular Weight: 632
CAS: NA
Q Qatio: 2.2
Anabolic #: 210
Androgenic #: 95
Oral Bioavailability: Estimated at 40%
AR Binding Affinity: NA
SHBG Binding Affinity: NA
Half Life: NA
Legal Status (US): Not listed as a controlled substance
Average Dose:
20-40mg/day standalone
10-20mg/day when stacked
Average Cycle Length: 2-4 weeks
Stimulator
Inhibitor

-5
-4
-3
-2
-1

0
1
2
3
4
5

Muscle Gain

[][][][]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Strength Gain

[][][][]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Fat Gain (negative indicates fat loss)

[]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Water Retention (extra-cellular bloat)

[]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Aggression

[][]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Libido

[]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Acne

[]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Hair Loss

[][]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Prostate Enlargement

[][]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Liver Toxicity

[][][][][]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Lethargy

[]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Characteristics

Dimethazine is actually two steroid molecules bound together by a nitrogen atom. Upon ingestion, stomach acid separates the two steroid molecules that closely resemble methyldrostanolone (Superdrol).

Although dimethazine appears very similar to methyldrostanolone, the presence of a nitrogen at the 3rd position appears to increase its androgenic potency relative to its anabolic potency (210/95 compared to 400/20 for methyldrostanolone). Therefore, dimethazine could be considered a slightly weaker form of methyldrostanolone, but perhaps less likely to cause gyno related issues because of its higher relative androgenic value (and ability to antagonize estrogenic effects).

Otherwise, all side-effects and benefits could be considered relatively the same as methyldrostanolone. Liver toxicity and its associated side-effects of general sickness should still be expected, especially if the liver becomes compromised. Using a liver protecting supplement prior to and during a cycle of Dimethazine would be very important.

The quick gains in size and strength will likely be accompanied by increases in intense back pumps, high blood pressure, shortness of breath and oily skin. Vascularity would also be expected to improve with this compound due to the increase in extra-cellar water and possible decrease in subcutaneous water weight.

Because this compound is a 17aa oral, it is not recommended to be stacked with other 17aa oral steroids.

Common Clones:

Dymethazine by IForce


Related Discussion

The Official Dimethazine Thread
Posted by Eric

References

“Oral administration of an anabolic-androgenic steroid dimethazine increases the growth and food conversion efficiency and brings changes in molecular growth responses of carp (Cyprinus carpio) tissues”

LONE K. P. (1) ; MATTY A. J. ;
Nutrition reports international

“Contribution to the study of the proteoanabolic effects of dimethazine. (Clinical research)”
CEI C, ANSELMI G.
Gazz Med Ital. 1963 Feb;122:57-61

“A new steroid having proteo-anabolic action: dimethazine.”
DE RUGGIERI P, MATSCHER R, GANDOLFI C, CHIARAMONTI D, LUPO C, PIETRA E, CAVALLI R.Arch Sci Biol (Bologna). 1963 Jan-Mar;47:1-19.

%d bloggers like this: